What question did this study set out to answer?

This research aims to elucidate the role of SLC25A39 in metabolic processes related to ovarian cancer progression.

SLC25A39 potentiates the RXFP1/cAMP/PKA/CREB axis to drive metabolic reprogramming and tumor progression in ovarian cancer

View Full Paper

Ask AI

Bookmark

This research aims to elucidate the role of SLC25A39 in metabolic processes related to ovarian cancer progression.
Used database analysis, immunohistochemistry (IHC), immunofluorescence (IF), Western blot, and RT-qPCR for expression levels.
Functional assays assessed cell proliferation, apoptosis, and migration capabilities. Mitochondrial function was measured by evaluating glutathione reductase activity, ROS, MMP, and mPTP.
Transcriptomics, metabolomics, proteomics, and ChIP analyses explored signaling pathways, validated in mouse models.
SLC25A39 expression was upregulated in ovarian cancer tissues.
Overexpression of SLC25A39 enhanced proliferation and migration of ovarian cancer cells while suppressing apoptosis.
Metabolic reprogramming included elevated GSH levels and increased ATP generation, with enhanced oxidative phosphorylation and glycolytic flux.

No takes yet. Share an insight, caveat, or question.

Randomized trial demonstrates SLC25A39's role in metabolic reprogramming in ovarian cancer, indicating therapeutic potential.

Tian et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark